Etiology of serum CA-125 in patients with endometriosis treated with a gonadotrophin-releasing hormone agonist (Buserelin)

Basit Öğe Kaydı
dc.authorid0000-0002-8335-1927en_US
dc.contributor.authorÇetin, T
dc.contributor.authorVardar, Mehmet Ali
dc.contributor.authorDemir, C.
dc.contributor.authorBurgut, Hüseyin Refik
dc.date.accessioned2024-07-12T21:03:56Z
dc.date.available2024-07-12T21:03:56Z
dc.date.issued1994en_US
dc.departmentFakülteler, Tıp Fakültesien_US
dc.description.abstractFifty-six patients with pelvic endometriosis were treated with a buserelin dosage of 200 µg/day s.c. for 6 months. Scoring of the American Fertility Society (AFS) for endometriosis was performed by laparoscopy in all cases before and at the end of therapy. Serum CA-125 and estradiol levels were determined before the treatment, and monthly during therapy and follow-up (6 months; respectively). A slight positive correlation was found between serum CA-125 concentrations before treatment and AFS scores for adhesions only. Before treatment, serum CA-125 values also correlated slightly with total AFS scores of patients with adhesions. At the end of the 6-month therapy, no correlation was found between CA-125 concentrations and second-look AFS scores for implants and/or adhesions. Serum CA-125 and estradiol values were closely parallel to each other during and after therapy with the gonadotrophin-releasing hormone agonist buserelin. In conclusion, (1) adhesions may play a role in the elevation of serum CA-125 levels in endometriosis, and (2) a significant decrease in serum CA-125 values during the buserelin therapy may result from a rather different mechanism, such as ovarian suppression, other than the therapeutic effect of this agent.en_US
dc.identifier.citationÇetin, T., Vardar, M. A., Demir, C. ve Burgut, H. R. (1994). Etiology of serum CA-125 in patients with endometriosis treated with a gonadotrophin-releasing hormone agonist (Buserelin). Karger Publishing. 38(4), s. 294-252.en_US
dc.identifier.endpage252en_US
dc.identifier.issn1423-002X
dc.identifier.issue4en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage294en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12415/3733
dc.identifier.volume38en_US
dc.institutionauthorBurgut, Hüseyin Refik
dc.language.isoenen_US
dc.publisherKarger Publishingen_US
dc.relation.ispartofGynecologic and Obstetric Investigationen_US
dc.relation.isversionof10.1159/000292491en_US
dc.relation.publicationcategoryUluslararası Hakemli Dergide Makale - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKY01106
dc.subjectEndometriosisen_US
dc.subjectCA-125en_US
dc.subjectBuserelinen_US
dc.titleEtiology of serum CA-125 in patients with endometriosis treated with a gonadotrophin-releasing hormone agonist (Buserelin)en_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

Tıp Fakültesi Koleksiyonu